This paper explores the optimal drug strategy for non-small cell lung cancer with epidermal growth factor receptor(EGFR)ex20ins mutation.The clinical data of a case of non-small cell lung cancer with EGFR ex20ins mutation was collected,and explored it through monitoring the treatment process,literature review and post-medication analysis.In this case,both allmetinib and osimertinib are third-generation tyrosine kinase inhibitors(TKIs),and switching from allmetinib to afatinib is not the best medication strategy.For non-small cell lung cancer with EGFR ex20ins mutation,pemetrexed+cisplatin(PP)regimen can be the best choice for chemotherapy,and osimertinib or Almetinib is the best choice for targeted drugs.
关键词
非小细胞肺癌/表皮生长因子受体20外显子插入突变/合理用药
Key words
Non-small cell lung cancer/Epidermal growth factor receptor ex20ins mutation/Rational drug use
维普
万方数据